Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
The antibacterial activity of levofloxacin was compared with those of ofloxacin and ciprofloxacin against bacterial isolates from patients with cancer. In general, levofloxacin was as active or was twofold more active than ofloxacin and was two- to fourfold less active than ciprofloxacin against most gram-negative pathogens. Against Pseudomonas aeruginosa, ciprofloxacin was the most active agent tested (MIC for 90% of isolates tested, 1.0 microgram/ml). Overall, all three agents had similar activities against gram-positive organisms and were moderately active against methicillin-susceptible Staphylococcus aureus and coagulase-negative staphylococci, Streptococcus species, and Enterococcus species.
15 references, click to expand
-
Norfloxacin for prevention of bacterial infections in granulocytopenic patients.Am J Med. 1987 Jun 26;82(6B):40-6 PMID: 3037899
-
Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin.Ann Intern Med. 1987 Jan;106(1):7-11 PMID: 3466563
-
In vitro activity of DR-3355, an optically active ofloxacin.Antimicrob Agents Chemother. 1988 Sep;32(9):1336-40 PMID: 3195996
-
Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients.Antimicrob Agents Chemother. 1989 Jan;33(1):87-91 PMID: 2653217
-
Intravenous ciprofloxacin for infections in cancer patients.Am J Med. 1989 Nov 30;87(5A):261S-265S PMID: 2589375
-
Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.Am J Med. 1989 Nov 30;87(5A):278S-282S PMID: 2686429
-
In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin.Chemotherapy. 1990;36(4):268-76 PMID: 2174762
-
In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.Antimicrob Agents Chemother. 1992 Apr;36(4):860-6 PMID: 1503449
-
In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.Antimicrob Agents Chemother. 1992 Apr;36(4):879-82 PMID: 1503453
-
Synergy of levofloxacin (L-ofloxacin) and oxacillin against quinolone-resistant Staphylococcus aureus, measured by the time-kill method.Antimicrob Agents Chemother. 1993 Feb;37(2):339-41 PMID: 8452367
-
Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer.Cancer. 1993 Jun 1;71(11):3640-6 PMID: 8490912
-
Ciprofloxacin-induced nephrotoxicity in patients with cancer.Arch Intern Med. 1993 May 24;153(10):1258-62 PMID: 8494478
-
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.Antimicrob Agents Chemother. 1985 Oct;28(4):581-6 PMID: 3000292
-
Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.Ann Intern Med. 1987 Jan;106(1):1-7 PMID: 3538962
-
A clinical, microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients.J Antimicrob Chemother. 1988 May;21(5):647-55 PMID: 3391864
Contact
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
WeChat Official Account
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: product@genelibs.com
Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2
